Dabigatran and rivaroxaban for prevention of venous thromboembolism - Systematic review and adjusted indirect comparison

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 1, 2011, Pages 111-124

  Loke, Y K ^a   Kwok, C S ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

anticoagulation; dabigatran; oral direct thrombin inhibitors; oral factor Xa inhibitors; rivaroxaban; venous thromboembolism

Indexed keywords

DABIGATRAN; ENOXAPARIN; RIVAROXABAN;

ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HUMAN; LUNG EMBOLISM; META ANALYSIS (TOPIC); MORTALITY; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; ENOXAPARIN; FACTOR XA; HEMORRHAGE; HUMANS; MORPHOLINES; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; THIOPHENES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 78650937277     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01162.x     Document Type: Article

References (29)

1. Karthikeyan G, Eikelboom JW, Hirsh J, (2009) New oral anticoagulants: not quite there yet. Polskie Archiwum Medycyny Wewnetrznej, 119, 53-59.
2. National Institute for Health and Clinical Excellence UK (2008) NICE Technology Appraisal Guidance 157-Dabigatran Etexilate for the Prevention of Venous Thromboembolism After Hip or Knee Replacement Surgery in Adults. Available at: (accessed 24 September 2008).
3. National Institute for Health and Clinical Excellence UK (2009) NICE Technology Appraisal Guidance 170-Rivaroxaban for the Prevention of Venous Thromboembolism After Total Hip or Total Knee Replacement in Adults. Available at: (accessed 22 April 2009).
4. Canadian Expert Drug Advisory Committee (2008) Final Recommendation and Reasons for Recommendation-Rivaroxaban. Available at: (accessed 17 December 2008).
5. Canadian Expert Drug Advisory Committee (2009) Final Recommendation on Reconsideration and Reasons for Recommendation-Dabigatran. Available at: (accessed 28 January 2009).
6. Loke YK, Price D, Herxheimer A, (2008) Chapter 14: Adverse effects. In:, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available at: (accessed 3 February 2010).
7. Deeks JJ, Higgins JP, Altman DG, (2008) Analysing data and undertaking meta-analyses. In:, Higgins JG, Green S, eds. Cochrane handbook for systematic reviews of interventions Version 5.0.1. (updated September 2008). The Cochrane Collaboration, 2008. Available at: (accessed 3 February 2010).
8. Bucher HC, Guyatt GH, Griffith LE, Walter SD, (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology, 50, 683-691.
9. Wells GA, Sultan SA, Chen L, Khan M, Coyle D, (2009) Indirect treatment comparison [computer program] 1.0 edn. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available at: (accessed 3 February 2010).
10. Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG, (2009) Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. British Medical Journal, 338, b1147.
11. Cates C, (2009) Dr Chris Cates' EBM. Available at: (accessed 24 September 2009).
12. Kakkar AK, Brenner B, Dahl OE, et al., (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet, 372, 31-39.
13. Eriksson BI, Borris L, Dahl OE, et al., (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. Journal of Thrombosis and Haemostasis, 4, 121-128.
14. Eriksson BI, Borris LC, Dahl OE, et al., (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [see comment]. Circulation, 114, 2374-2381.
15. Eriksson BI, Borris LC, Friedman RJ, et al., (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine, 358, 2765-2775.
16. Lassen MR, Ageno W, Borris LC, et al., (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. New England Journal of Medicine, 358, 2776-2786.
17. Turpie AG, Lassen MR, Davidson BL, et al., (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet, 373, 1673-1680.
18. Turpie AGG, Fisher WD, Bauer KA, et al., (2005) BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis, 3, 2479-2486.
19. Ginsberg JS, Davidson BL, Comp PC, et al., (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. Journal of Arthroplasty, 24, 1-9.
20. Eriksson BI, Dahl OE, Rosencher N, et al., (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. [see comment]. Journal of Thrombosis and Haemostasis, 5, 2178-2185.
21. Eriksson BI, Dahl OE, Rosencher N, et al., (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. [see comment] [erratum appears in Lancet. 2007 Dec 15;370(9604):2004]. Lancet, 370, 949-956.
22. Di Nisio M, Middeldorp S, Buller HR, (2005) Direct thrombin inhibitors. New England Journal of Medicine, 353, 1028-1040.
23. Mann KG, Brummel K, Butenas S, (2003) What is all that thrombin for? Journal of Thrombosis and Haemostasis, 1, 1504-1514.
24. Bauer KA, (2006) New anticoagulants: anti IIa vs anti Xa-is one better? Journal of Thrombosis and Thrombolysis, 12, 67-72.
25. Stangier J, Eriksson BI, Dahl OE, et al., (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Journal of Clinical Pharmacology, 45, 555-563.
26. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M, (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. European Journal of Clinical Pharmacology, 61, 873-880.
27. Song F, Altman DG, Glenny AM, Deeks JJ, (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. British Medical Journal, 326, 472-476.
28. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI, (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. [see comment]. Thrombosis and Haemostasis, 101, 77-85.
29. Fisher WD, Eriksson BI, Bauer KA, et al., (2007) Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thrombosis and Haemostasis, 97, 931-937.